Coherus BioSciences Inc at Barclays Global Healthcare Conference Transcript
Hi. Good morning. My name's Doug Tsao from Barclays. To kick start the proceedings for the day, we have with us Jean Viret, CFO from Coherus Biosciences; and also David, who heads VP IR and Corporate Communications, Corporate Affairs. So Jean Viret, over to you, please.
©© -
Thank you, Doug Tsao, and welcome, everyone. I want to thank our friends at Barclays for inviting us again this year at their health care conference. Today, I'll be making forward-looking statements. These forward-looking statements have certain risks and uncertainties that are described in our Form 10-K that was just submitted to the SEC. So I encourage you to look at the uncertainties submitted in this document.
Today, I'm going to cover 3 areas. First, I'm going to do a company summary. Second, I'll also spend quite a bit of time on our UDENYCA launch. UDENYCA is our pegfilgrastim and biosimilar. And lastly, I
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
